Welcome to BioMed Central's Cancer Gateway, highlighting the latest articles we have published in this field. Content is continually updated, so please bookmark this page and ensure you check it regularly.
Adipose cells in the tumour microenvironment may be contributing to resistance to Trastuzumab, a targeted treatment for HER2+ breast cancer.
Moyano and Stefani review key evidence for the role of piRNAs and PIWI in cancers deriving from both germline cells and somatic tissues, and how we can discriminate between a ‘passenger’ vs. a ‘driver’ role in the pathogenesis of these diseases.
Long non-coding RNA profiles were found to predict risk of metastases in lymph node-negative breast cancer patients, and hence may be a source of prognostic information used to combat overtreatment.
Humphrey and Kasinski report on recently developed CRISPR-Cas platforms for global genome editing and address the therapeutic potential of CRISPR-Cas technology for genome-wide functional studies of disease processes, as well as applications beyond genome editing.
Sanchez-Mejias and Tay review recent discoveries that implicate competing endogenous RNAs (ceRNAs), or natural miRNA sponges, in human cancer. The authors explain how identifying ceRNA regulatory networks can aid the development of new approaches to cancer diagnostics and oligonucleotide-based therapeutics.
The levels of four urinary miRNAs that are specifically altered in breast cancer patients compared to healthy controls may serve as potential non-invasive innovative biomarkers to detect primary breast cancer.
Nicola Normanno and Ian Cree comment on the role of genomics in oncology, and the issues to overcome before targeted treatment based on genomic profile can become routinely accessible to lung cancer patients.
Cancers of unknown primary origin (CUP) exhibit distinct molecular features compared to metastases of known origin and display signatures of chromosome instability which may account for their uncommon clinical presentation and poor outcome.
Authors of BioMed Central cancer-related articles, by location
Powered by AuthorMapper.com
Cancer and obesity series
We are pleased to invite you to submit your manuscript to a new cross-journal thematic series, Cancer and Obesity. BioMed Central is launching this series in response to the call for increased education, research and advocacy to reduce the toll of obesity as a leading cause of cancer, and a complication in the care of cancer patients.
This collection will explore the biological, translational and clinical links between obesity of and cancer, including the molecular, genetic and hormonal causes of obesity-linked cancers, the impact of behavior change on cancer outcomes, and the impact of obesity on the diagnosis and treatment of cancer.
The following journals will be accepting submissions:
- BMC Cancer
- Cancer & Metabolism
- Clinical Epigenetics
- Gynecologic Oncology Research and Practice
- Journal of Hematology & Oncology
- Journal of Translational Medicine
Please submit your article via the online submission system and indicate in your cover letter that you would like your article to be considered for the Cancer and Obesity series.
For further information please contact: email@example.com.
Cancer news from around the web
- 01 May 2015
- Comprehensive look at brain cancer treatments
- 01 May 2015
- How to reset a diseased cell
- 01 May 2015
- New potential melanoma drug target discovered